A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 3
- Study design
- RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE
- Evidence population
- Human clinical study registration
- Participants
- 630
- Population
- ALL · 50 Years
- Duration
- 2022-11-18 to 2026-07-01
- Intervention
- Bevacizumab; Ranibizumab Ophthalmic
- Comparator
- Ranibizumab, RBZ (group B)
- Outcomes measured
- Frequency of Genetic Polymorphism in VEGFA Associated With Anti-VEGF Treatment Response in AMD Patients — From baseline…; Change in Visual Acuity Over Time in Patients With AMD Receiving Anti-VEGF Therapy — Baseline, 6 months, 12 months, 24…; Change in Retinal Fluid and Foveal Thickness Over Time as Measured by OCT in Patients With AMD Treated With Anti-VEGF T…; Distribution of Sex Among Patients With AMD Receiving Anti-VEGF Therapy — At baseline; Distribution of Age at Diagnosis in Patients With AMD Receiving Anti-VEGF Therapy — At baseline; Proportion of Smokers Among Patients With AMD Receiving Anti-VEGF Therapy — At baseline; Weight of Patients With AMD Receiving Anti-VEGF Therapy — At baseline; Height of Patients With AMD Receiving Anti-VEGF Therapy — At baseline; Prevalence of Obesity in Patients With AMD Receiving Anti-VEGF Therapy — At baseline; Prevalence of Hypertension in Patients With AMD Receiving Anti-VEGF Therapy — At baseline; Number of Participants With Ocular and Systemic Adverse Events Associated With Intravitreal Anti-VEGF Therapy — From in…; Total Direct Healthcare Cost per Patient for Anti-VEGF Therapy Over One Year From the Health System Perspective — From…
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 100%Abstract contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Abstract supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 85%. These figures help sort records; they are not medical ratings.